BCBicycle Therapeutics plc BCYC · NASDAQ
$3.64 +1.96% (+$0.07)
- Market cap
- $254.1M
- Enterprise value
- -$242.2M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 4.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -38.0%
- Gross margin
- 100.0%
- Net margin
- -311.1%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.68
- Free float
- 88.6%
About the company
Bicycle Therapeutics (BCYC) is a biotechnology company based in the United Kingdom that focuses on developing novel therapeutics based on bicycle peptide technology. This technology enables the creation of small, stable, and highly specific therapeutics with the potential to treat various diseases, including cancer and immune-related disorders. Bicycle Therapeutics is dedicated to developing drugs based on its bicycle peptide platform and building partnership agreements with pharmaceutical companies.
Sector
Healthcare
Industry
Biotechnology
CEO
Kevin Lee
Employees
288
Headquarters
Cambridge
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number